RGNX REGENXBIO Inc

Price (delayed)

$18.2

Market cap

$791.08M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.25

Enterprise value

$812.26M

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, ...

Highlights

RGNX's EPS is up by 3.8% since the previous quarter

The net income is up by 3.6% from the previous quarter

RGNX's gross profit has dropped by 84% year-on-year but it is up by 15% since the previous quarter

The gross margin has declined by 30% year-on-year but it has increased by 18% since the previous quarter

The company's revenue has shrunk by 77% YoY and by 2.7% QoQ

The equity has contracted by 33% YoY and by 10% from the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://www.regenxbio.com

Peers: OVID

Key stats

What are the main financial stats of RGNX

Market

Shares outstanding

43.47M

Market cap

$791.08M

Enterprise value

$812.26M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

1.7

Price to sales (P/S)

7.21

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

7.41

Earnings

Revenue

$109.64M

EBIT

-$250.44M

EBITDA

-$235.94M

Free cash flow

-$257.07M

Per share

EPS

-$6.25

Free cash flow per share

-$5.92

Book value per share

$10.7

Revenue per share

$2.52

TBVPS

$17.21

Balance sheet

Total assets

$747.83M

Total liabilities

$282.69M

Debt

$93.3M

Equity

$465.14M

Working capital

$276.87M

Liquidity

Debt to equity

0.2

Current ratio

3.46

Quick ratio

3.15

Net debt/EBITDA

-0.09

Margins

EBITDA margin

-215.2%

Gross margin

60.8%

Net margin

-246.5%

Operating margin

-234.9%

Efficiency

Return on assets

-31.6%

Return on equity

-49.7%

Return on invested capital

-34.7%

Return on capital employed

-39.4%

Return on sales

-228.4%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

RGNX stock price

How has the REGENXBIO stock price performed over time

Intraday

-0.33%

1 week

-9.18%

1 month

-1.09%

1 year

-9.81%

YTD

-19.75%

QTD

-3.75%

Financial performance

How have REGENXBIO's revenue and profit performed over time

Revenue

$109.64M

Gross profit

$66.7M

Operating income

-$257.51M

Net income

-$270.27M

Gross margin

60.8%

Net margin

-246.5%

RGNX's gross profit has dropped by 84% year-on-year but it is up by 15% since the previous quarter

The company's revenue has shrunk by 77% YoY and by 2.7% QoQ

The gross margin has declined by 30% year-on-year but it has increased by 18% since the previous quarter

The net income is up by 3.6% from the previous quarter

Growth

What is REGENXBIO's growth rate over time

Valuation

What is REGENXBIO stock price valuation

P/E

N/A

P/B

1.7

P/S

7.21

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

7.41

RGNX's EPS is up by 3.8% since the previous quarter

RGNX's P/B is 47% below its 5-year quarterly average of 3.2 and 6% below its last 4 quarters average of 1.8

The equity has contracted by 33% YoY and by 10% from the previous quarter

The company's revenue has shrunk by 77% YoY and by 2.7% QoQ

The price to sales (P/S) is 49% lower than the 5-year quarterly average of 14.2 but 39% higher than the last 4 quarters average of 5.2

Efficiency

How efficient is REGENXBIO business performance

The ROE is down by 6% QoQ

REGENXBIO's ROA has decreased by 4.3% from the previous quarter

The ROIC has contracted by 2.4% from the previous quarter

Dividends

What is RGNX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RGNX.

Financial health

How did REGENXBIO financials performed over time

RGNX's total assets is 165% greater than its total liabilities

RGNX's total assets is down by 27% year-on-year and by 10% since the previous quarter

RGNX's total liabilities is down by 16% year-on-year and by 11% since the previous quarter

REGENXBIO's debt is 80% lower than its equity

RGNX's debt to equity has soared by 54% year-on-year and by 11% since the previous quarter

The equity has contracted by 33% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.